Telbolife H 80 Tablet is a potent combination antihypertensive formulation consisting of Telmisartan (80 mg) and Hydrochlorothiazide (12.5 mg). This dual-action therapy is specifically developed for patients who require stronger blood pressure control. It combines the efficacy of an angiotensin II receptor blocker (Telmisartan) with a thiazide diuretic (Hydrochlorothiazide) to effectively lower and stabilize high blood pressure (hypertension).
Telmisartan works by blocking the action of angiotensin II, a hormone that narrows blood vessels and elevates blood pressure. By preventing this action, Telmisartan relaxes the blood vessels, allowing smoother blood flow and reducing overall vascular resistance. Hydrochlorothiazide, meanwhile, promotes the elimination of excess salt and water through urine, which helps reduce blood volume and subsequently lowers blood pressure.
The combination is ideal for patients not adequately controlled with monotherapy, especially those with a high cardiovascular risk profile. Telbolife H 80 not only helps in maintaining consistent 24-hour blood pressure control but also reduces the likelihood of cardiovascular events such as heart attack and stroke when used long-term.
This once-daily formulation improves patient compliance while offering the convenience of two powerful medications in a single tablet. It is particularly useful for managing essential hypertension, resistant hypertension, and hypertension associated with conditions like diabetes, kidney disease, or obesity.
Patients on Telbolife H 80 should be advised to monitor blood pressure regularly and adopt a heart-healthy lifestyle including dietary modifications, regular exercise, and reduction of salt intake. Periodic blood tests may be required to monitor electrolyte levels and kidney function.